Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord-derived mesenchymal stem cells (AP-HP)
- Development stage
- Unknown
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of allogeneic umbilical cord-derived mesenchymal stromal cells (UC-MSCs) developed by Assistance Publique - Hôpitaux de Paris (AP-HP) for the treatment of severe, refractory systemic lupus erythematosus (SLE). The therapy leverages the immunomodulatory, proangiogenic, and antifibrotic properties of mesenchymal stromal cells to reset the immune balance in patients who have failed standard-of-care treatments. Administered as a single intravenous infusion, these cells are manufactured from a single umbilical cord. The therapy has been evaluated in a Phase 1/2 clinical trial (NCT03562065) to assess safety and preliminary efficacy in reducing disease activity, as measured by the SELENA-SLEDAI score, in patients aged 18-70 years.
- Other names
- UC-MSCsAllogeneic umbilical cord-derived mesenchymal stromal cellsUmbilical cord-derived mesenchymal stem cells
Beyond the preview
Go deeper on Umbilical cord-derived mesenchymal stem cells (AP-HP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Umbilical cord-derived mesenchymal stem cells (AP-HP).